Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 2
2004 1
2005 1
2008 1
2009 1
2010 1
2011 2
2012 7
2013 6
2014 7
2015 5
2016 9
2017 10
2018 8
2019 8
2020 10
2021 12
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Results by year
Filters applied: . Clear all
Page 1
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Brose MS, et al. Among authors: sherman ej. Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23. Lancet Oncol. 2016. PMID: 27460442 Free PMC article. Clinical Trial.
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Ang KK, et al. Among authors: sherman ej. J Clin Oncol. 2014 Sep 20;32(27):2940-50. doi: 10.1200/JCO.2013.53.5633. J Clin Oncol. 2014. PMID: 25154822 Free PMC article. Clinical Trial.
Identification of ACE2 modifiers by CRISPR screening.
Sherman EJ, Mirabelli C, Tang VT, Khan TG, Kennedy AA, Graham SE, Willer CJ, Tai AW, Sexton JZ, Wobus CE, Emmer BT. Sherman EJ, et al. bioRxiv. 2021 Jun 10:2021.06.10.447768. doi: 10.1101/2021.06.10.447768. Preprint. bioRxiv. 2021. PMID: 34127970 Free PMC article.
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers.
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM. Subbiah V, et al. Among authors: sherman ej. Cancer Discov. 2020 May;10(5):657-663. doi: 10.1158/2159-8290.CD-19-1265. Epub 2020 Feb 6. Cancer Discov. 2020. PMID: 32029534 Free PMC article.
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL. Dunn LA, et al. Among authors: sherman ej. J Clin Endocrinol Metab. 2019 May 1;104(5):1417-1428. doi: 10.1210/jc.2018-01478. J Clin Endocrinol Metab. 2019. PMID: 30256977 Free PMC article.
Targeting VEGF and EGFR: a combination worth re-exploring?
Tchekmedyian V, Sherman EJ. Tchekmedyian V, et al. Among authors: sherman ej. Lancet Oncol. 2018 Aug;19(8):1007-1009. doi: 10.1016/S1470-2045(18)30377-2. Epub 2018 Jul 11. Lancet Oncol. 2018. PMID: 30001988 No abstract available.
83 results